¹ Utility of Pan-Family Assays for Rapid Viral

- ² Screening: *Reducing Delays in Public Health*
- **3** Responses During Pandemics
- 4
- 5 Michael Erlichster^{1*}, Gursharan Chana^{1,2}, Daniela Zantomio³, Benjamin
- 6 Goudey^{4,5}, Efstratios Skafidas^{1,6}
- 7
- 8 ¹ MX3 Diagnostics, Melbourne, Victoria, Australia
- 9 ² Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne,
- 10 Victoria, Australia
- ³ Department of Haematology, Austin Health, Heidelberg, Victoria, Australia
- ⁴ IBM Research Australia, Southbank, Victoria, Australia.
- 13 ⁵ Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne,
- 14 Victoria, Australia
- ⁶ Department of Electrical and Electronic Engineering, Melbourne School of Engineering,
- 16 The University of Melbourne, Melbourne, Victoria, Australia
- 17
- 18 *Corresponding Author. Email <u>erlichster@mx3diagnostics.com</u>

19 Summary

20 Background

The SARS-CoV-2 pandemic has highlighted deficiencies in the testing capacity of many developed countries during the early stages of emerging pandemics. Here we describe the potential for pan-family viral assays to improve early accessibility of large-scale nucleic acid testing.

25 Methods

Coronaviruses and SARS-CoV-2 were used as a case-study for investigating the utility of panfamily viral assays during the early stages of a novel pandemic. Specificity of a pancoronavirus (Pan-CoV) assay for viral detection was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to SARS-CoV-2 and 59 other coronavirus species. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression.

33 Findings

Due to infection with common HCoV species, a Pan-CoV assay would return a false positive for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients displaying symptoms of respiratory disease. Two of the four reported pan-coronavirus assays would have identified SARS-CoV-2 and we demonstrate that with small adjustments to the primers, these assays can accommodate novel variation observed in animal coronaviruses. The assay target region of one well established Pan-CoV assay is highly resistant to mutation compared to regions targeted by other widely applied SARS-CoV-2 RT-PCR assays.

41

43 Interpretation

Pan-family assays have the potential to greatly assist management of emerging public health emergencies through prioritization of high-resolution testing or isolation measures, despite limitations in test specificity due to cross-reactivity with common pathogens. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation of a given virus. This approach may be applicable to other viral families and has utility as part of a strategic stockpile of tests maintained to better contain spread of novel diseases prior to the widespread availability of specific assays.

51 Introduction

52 During the early stages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic many countries exhibited an extreme shortage of SARS-CoV-2 nucleic acid test 53 54 kits. This resulted in a weeks to months-long period where testing could only be performed in 55 a limited capacity at select test centers, with a focus on symptomatic patients with a history of 56 travel or association with a known case. The inability to perform extensive testing was 57 particularly impactful in the current pandemic due to the greater than normal infectivity of 58 asymptomatic patients¹, placing a greater burden on molecular diagnostic tools for identifying 59 and containing disease spread. The precise cause of this shortage has not yet been fully 60 investigated but is likely a combination of the unprecedented global demand for test reagents 61 and equipment, disruption to supply chains caused by the pandemic and regulatory restrictions limiting the ability of some nations to expand test capacity². These shortcomings highlight that 62 63 the current testing infrastructure and capacity expansion strategies are not rapid enough to 64 counter disease spread during the early stages of some pandemics.

65 In response to SARS-CoV-2, governments will likely invest in a more extensive and agile 66 network of testing equipment, stockpile test reagents and consumables and streamline test 67 certification protocols. While this will greatly enhance the speed at which testing capacity can 68 be increased, there will still be a vital period between the time a novel pathogen emerges and 69 the time that tests are widely available at high capacity, which can hamper efforts to contain 70 disease spread. A strategy which may allow wide-spread testing of novel pathogens in a more-71 timely manner is the use of pre-emptively developed pan-family assays: molecular diagnostic 72 tests targeted at a family of viruses rather than a single species. Pan-family assays targeting several viral families have been developed for research applications and are routinely used 73 74 during pathogen characterization and in retrospective epidemiological studies^{3,4}.

To reduce the likelihood of severe test shortages in future pandemics, we propose a proactive strategy involving the large-scale stockpiling of pan-family targeted PCR diagnostic kits for use during the early stages of viral pandemics (**Figure 1**). In this strategy, pan-family tests are developed, certified and stockpiled in large volume prior to disease emergence. Following confirmation of test applicability to the novel pathogen, it may then be applied to deliver unrestricted testing while a species-specific test is produced.

81 Here we assess, using coronaviruses and SARS-CoV-2 as a case study, whether pan-family 82 targeted assays are a practical tool for high-throughput screening of infection during the early 83 stages of a pandemic. We consider the frequency of common viral species, the capability of 84 reported pan-family assays to accommodate observed variation and the mutation rate of the 85 pan-family assay target regions. Given the significant global economic and social disruption 86 caused by the SARS-CoV-2 pandemic, we argue that despite some limitations in the specificity 87 and sensitivity of pan-family assays, a strategic stockpile is prudent as a first-line mass-88 screening technique.



91 Figure 1. Current and proposed viral disease testing strategies. In the current strategy a 92 delay of weeks to months is observed between disease emergence and unrestricted testing, 93 allowing a disease to spread. By using pan-family tests widespread testing is available in a 94 shortened timeframe and disease spread may be contained.

95 Methods

96 Review of common HCoV epidemiolocal characteristics

97 A search using the terms "HCoV" "epidemiology" and "asymptomatic" was performed in 98 PubMed to identify studies describing HCoV infection characteristics. Studies highlighting the 99 following aspects of HCoV infection were selected and summarized; frequency in children or 100 the elderly, frequency in asymptomatic individuals, frequency in large study cohorts and 101 frequency during local epidemics.

102 Validation and modification of a reported Pan-CoV assays

103 Coronavirus-family reference sequences were identified and downloaded from the NCBI Virus 104 database⁵. Sequences for a total of 60 species were identified (**Supplementary Table 1**), 105 including the 7 species known to infect humans (HCoV-229E, HCoV-NL63, HCoV-HKU1 106 and HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2). Pan-coronavirus assay primer 107 targets were derived from four reported assays⁶⁻⁹ and aligned with the SARS-CoV-2 reference 108 genome (NC 045512) to assess consensus between sequences using the Clustal Omega

109 Multiple Sequence Alignment tool¹⁰.

The nucleic acid sequence and predicted protein sequence for each species was aligned and assessed for identity with Pan-CoV primer targets using the software package Geneious Prime 2020.1.2 (<u>https://www.geneious.com</u>). Primers were modified to accommodate observed nucleic acid variation as well as nucleic acid sequences expected from the observed protein variation.

115 Assessment of the Pan-CoV primer target site mutation rate

116 Mutation frequency of the Pan-CoV target site was assessed using 8,899 high coverage (<1%

117 N calls and <0.05% unique amino acid mutations) full length (>29,000 base pairs) SARS-CoV-

118 2 genomes downloaded from the GISAID EpiCoV database¹¹. Analysis was performed with

- 119 the R Biostrings package¹² to identify mismatches in the primer target sites. Three samples
- 120 were excluded due to missing sequence data in the primer target region.

121 Results

122 Specificity of a Pan-CoV assay to a novel pathogen – impact of endemic coronavirus

123 species

124 A key factor in the utility of pan-family assays is the frequency of common species of the target 125 family in the general population, as these will interfere with the specificity of an assay for the novel pathogen. For the coronavirus family there are 4 endemic and common species that 126 127 infect humans (HCoV-229E, HCoV -NL63, HCoV-HKU1 and HCoV-OC43), typically causing mild disease but can lead to severe or fatal infections in frail or immunosuppressed 128 129 patients. It remains to be seen whether the current SARS-CoV-2 pandemic will persist at low 130 levels in the general population following disease control through social distancing, therapeutic measures or acquisition of herd immunity¹³. Non-endemic zoonotic coronavirus species 131 132 (SARS-CoV, MERS-CoV), while highly pathogenic, would not affect the specificity of a Pan-133 CoV assay for a novel pathogen as they are not observed at a relevant frequency. However, 134 Pan-CoV assay sensitivity to these pathogens is important as they are informative of species 135 with zoonotic potential.

136

137 Table 1 summarizes studies reporting the prevalence of common HCoV infection. HCoV infections are typically detected in 2-10% of patients exhibiting acute respiratory illness (ARI), 138 139 although during local HCoV epidemics frequency of infection may be as high as 30% in 140 symptomatic patients. Additionally, HCoV infections display a seasonality, typically observed 141 in winter months. Children, both experiencing ARI and asymptomatic have a high occurrence 142 of HCoV infection (4-10%). In asymptomatic adults HCoV infection is less well studied, but 143 reported values are lower at ~1%. Studies of seroprevalence of HCoV antibodies indicate that 144 virtually all individuals have had prior exposure to at least one form of coronavirus, with first

145	exposure common in childhood ¹⁴ . This high frequency of childhood infection may explain the
146	lower prevalence of asymptomatic infection in adults due to a partial acquired immunity ¹⁵ ,
147	though limited data exists describing the immunizing effect of HCoV infection ¹⁶ .
148	
149	Considering the observed frequencies of common coronavirus species (Table 1), a Pan-CoV
150	assay would be expected to be sufficiently specific for a novel pathogen to allow for broad
151	population screening, wherein a positive test is used to guide infection controls such as self-
152	isolation. The screening specificity is strongest in asymptomatic adults where only $\sim 1\%$ of the
153	population would be expected to return a false positive due to HCoV infection. Greater caution
154	must be taken in populations with a higher HCoV infection rate such as children, symptomatic
155	patients with comorbidities, or populations experiencing a local HCoV epidemic. Due to

156 relatively high frequency of common HCoV infection in these populations additional follow

157 up testing may be necessary to improve the utility to public health officials.

Study	Population	Observed HCoV infection rates	Ref.
Van der Zalm	230 respiratory samples	Overall – 8.7%	17
(2009)	routinely collected from	Asymptomatic – 7.7%	
	19 children across 6	Symptomatic Samples – 9.1%	
	months		
Gaunt (2010)	11,661 respiratory	Overall – 2.3%	18
	samples from 7,383	Asymptomatic - 1.08%	
	patients as part of routine	7-12 months old – 4.86%	
	respiratory virus		
	screening.		
Prill (2012)	1481 hospitalized	Overall – 7.5%	19
	children with ACI or	Hospitalized – 7.6%	
	fever and 742 controls.	Asymptomatic – 7.1%	
Cabeca (2013)	1087 respiratory samples	Overall – 7.7%	20
	from patients with ARI.	Asymptomatic Adults – 0.0%	
	50 Asymptomatic	All ARI patients - 8.1%	
	controls.	Patients with Comorbidities –	
		12.4%	
Lepiller (2013)	6,014 respiratory	Overall – 5.9%	21
	samples collected for	Immunosuppressed Patients- 6.7%	
	routine viral diagnostics.	During Local Epidemic – ~16%	
Matoba (2015)	4,342 respiratory	Overall – 7.6%	22
	samples from pediatric	During Local Epidemic – 28.5%	
	patients with ARTI		
Zhang (2015)	Meta-analysis of 489,651	Overall- 2.6%	23
	patients with ARTI		
Yip (2016)	8275 respiratory samples	Overall – 0.9%	24
	from patents with ARTI	0-10 years old – 0.9%	
		Over 80 years old - 1.5%	25
Liu (2017)	3.298 respiratory	Overall – 2.37%	25
	samples from pediatric	During Local Epidemic – 10%	
	patients with ARI		26
Zeng (2017)	11,399 respiratory	Overall – 4.3%	20
	samples from	7-12 months old $-5.9%$	
	hospitalized pediatric		
<u>X:11 1 (0010)</u>	patients with ARTI		27
Killerby (2018)	854,575 HCoV tests	Overall - 4.6%	27
	from 11 / Laboratories as	During Local Epidemic – 12.4%	
	part of routine		
	respiratory virus		
II: 11(2010)	screening.	0 11 0 10/	28
Heimdal (2019)	5,458 samples from	0 Verall - 9.1%	20
	nospitalized pediatric	Asymptomatic controls – 10.2%	
	patients with AKII and	nospitalizea – 9.1%	
	5/5 samples from		
	controls.		

158 **Table 1: Population Frequency of Common HCoV Infection in Highlighted Studies.** ARI

159 – Acute Respiratory Illness. ARTI – Acute Respiratory Throat Infection

160 <u>Sensitivity of Pan-CoV assays to a novel pathogen – performance of reported assays on</u>

161 observed coronavirus species from animal populations

162 Several consensus reverse-transcription PCR (RT-PCR) assays targeting the highly conserved 163 coronavirus RNA-dependent RNA polymerase gene with a pool of degenerate primers have been previously described for research applications⁶⁻⁹. These assays have been used to identify 164 and analyze previously unknown coronavirus species³ and perform retrospective analysis of 165 clinical samples to assess disease prevalence²⁰. 166 167 Figure 2 compares the target sequences of reported Pan-CoV assays with the SARS-CoV-2 168 reference genome. Only 2 of the 4 reported assays tested, the Moes/Vijgen (2005) update of 169 the Stephensen (1999) assay and the recent Hu (2018) assay, accommodate the SARS-CoV-2 170 genome without any primer-template mismatches. While these mismatches may not be

171 sufficient to prevent detection, they are undesirable as they may reduce reaction sensitivity²⁹.

172 This result highlights the importance of routine maintenance of pan-family assays, ensuing

173 degenerate primers accommodate annotated variation from animal populations.



175

Figure 2: Alignment of 4 Reported Pan-Coronavirus Primer Targets and the SARS-CoV-2 Genome.
IUPAC nucleotide code used where degenerate primers are reported. Each of the 5 rows shows a
different region of the SARS2 genome. Primers with mismatches between target sites and SARS-CoV2 genome are highlighted in yellow, with mismatches in red. Primers targets with a 100% match to the
SARS-CoV-2 genome highlighted in green.

In contrast to the other reported Pan-COV assays, the Moes/Vijgen assay (MPC) has a detailed protocol for analysis of respiratory pathogens in human samples⁷. To better predict the sensitivity of this assay to novel pathogens, we compared the MPC primer sequences to the respective primer target sites in the genomes of 60 coronavirus species (supplementary Table 2). The majority of these species were reported following the development of the MPC assay, and as such are informative of the capacity of existing tests to detect novel pathogens.

187

188 Of the 60 coronavirus reference sequences investigated, 20 contained a mismatch between the 189 MPC degenerate primer target and the viral genome, suggesting the MPC assay would be sub-190 optimal for detection of these species (Figure 3, Supplementary Table 1). Of these 20 species, 191 only 4 contained a genomic variant resulting in a change to the amino acid motifs encoded by 192 the target region. (Supplementary Table 2). This highlights the importance of accommodating 193 unobserved but likely variation, such as silent mutations, when designing pan-family assays. 194 Indeed, degenerate primers designed given the observed protein motifs of these 60 species 195 (Supplementary Tables 3) are identical to those designed from the observed sequence data 196 (Supplementary Table 4).



199



200 Figure 3: Sensitivity of the MPC Pan-CoV assay to coronavirus species observed in animal

201 populations. A complete sequence match between the MPC primer target and the genomic

sequence is observed for 40/60 (66.7%) of species, with a mismatch caused by a silent

203 mutation observed in 16/60 (26.7%) of species and a mismatch resulting in an amino acid

204 change observed in the remaining 4/60 (6.7%) of species.

205 **Resistance of the MPC target region to mutation**

Another application of a robust pan-family assay is as a fallback to protect against reduction in 206 207 test sensitivity of species-specific assays due to mutation of the viral pathogen during pandemic 208 progression. To assess the resilience of the MPC assay to mutation-derived errors, we assessed 209 mutation frequency of the MPC target sites in 8,893 high-coverage SARS-CoV-2 genomes. 210 Only a single sample with a mutation in the MPC target region was observed, 211 EPI ISL 414596, translating to an observed mutation rate of 0.01%. This is an order of magnitude lower than the observed mutation rate for the CDC primer regions (0.4-2.58%) and 212 213 the China CDC primer regions (0.74-16.19%) in the same dataset as reported on the GISAID 214 platform¹¹. These results indicate that the MPC target region is robust to mutation and may 215 provide ongoing value in the case of emergence of a viral strain with mutations in the target 216 regions of high specificity assays.

217 Discussion

218 Nucleic acid testing for the identification of infected individuals is one the most valuable tools 219 for controlling pathogen spread, especially for diseases with asymptomatic carriers. The recent SARS-CoV-2 pandemic has revealed deficiencies in the testing capacity of many countries, 220 221 resulting in a period where testing was highly restricted, preventing optimal disease 222 containment. The use of family-wide viral assays may reduce the time before mass testing is 223 available by allowing tests to be developed and distributed before pathogen emergence. Here 224 we demonstrate that a Pan-CoV test can be an effective tool for management of novel 225 coronavirus pathogens. These results may also be more broadly applicable for the 226 implementation of pan-family assays for the detection of pathogens from other viral families. 227 Table 2 summarizes the advantages and disadvantages of a Pan-family assay compared with the current high-specificity testing standard approach. 228

	Advantages	Disadvantages
Specific-	- High specificity provides confident	- Lack of availability during early stages
Virus Assay	diagnostic value.	of a pandemic.
	- Target optimization allows for detection	- Rush to develop and distribute in
	of very low vial load.	response to a novel pathogen may result
	- Well validated standard operating	in quality control issues.
	procedures for core technology.	
Pan-	- Stockpiling prior to pandemic	- Susceptible to off-target positives due to
Family	development enables rapid and	cross-reactivity with common
Assav	extensive population screening.	pathogens, reducing diagnostic value or
2	- Validated and quality controlled prior to	mandating follow up testing.
	pandemic development	- Sensitivity and specificity of testing
	- Can prioritize individuals for testing	dependent on viral family and
	with short-supply Specific Virus	population of interest.
	Assays.	

220	T 11 3 A 1	4 1	1 1 4	C D	e 9		1	• 41	
230	Table 2: Ad	vantages and	disadvantages	oi a pa	an-family a	assay co	ompared v	with	current

231 high-specificity approaches.

232 Coronaviruses are a useful framework for assessing the utility of pan-family testing as several 233 human coronaviruses are common globally and would interfere with specific identification of 234 a novel coronavirus pathogen. However, even without any further testing a Pan-CoV test still allows for a large majority (>90%) of individuals, particularly asymptomatic adults, to avoid 235 236 self-isolation measures with a negative test, though greater caution must be taken in 237 populations with a higher HCoV infection rate such as children, symptomatic patients with 238 comorbidities, or populations experiencing a local HCoV epidemic. This limitation can be 239 mitigated through multiple strategies, most simply application of this tool as a first-line screen 240 prior to confirmatory analysis with a more specific test. This would allow short-supply specific 241 tests to be reserved as a confirmatory, rather than a primary tool, enabling a higher-throughput 242 screen of large populations at ports-of-entry or for contact tracing during the early stages of 243 pandemic. An alternative strategy, not reliant on the presence of a specific test, would be the addition of a second exclusionary reaction targeting known common species³⁰, though this may 244 245 not be an effective tool where a novel pathogen is highly genetically similar to a common 246 species and may be overly burdensome for high-throughput population screening.

247

248 During the initial roll-out of SARS-CoV-2 testing kits by the CDC, several laboratories 249 experienced disruptions due to faulty testing kits³¹. Pan-family assays, developed prior to an 250 outbreak, would have a relaxed timeframe for test development, ensuring best-practice 251 validation, quality control procedures, regulatory certification and laboratory accreditation can 252 be achieved. Pan-family assays may also have additional ongoing utility as a fallback in the 253 case of quality control issues or disease mutations compromising the accuracy of specific assay 254 detection³². By targeting highly conserved regions and accommodating silent mutations, pan-255 family assays can be expected to be less prone to mutation induced errors, though routine 256 comparison of primer target sites with observed viral strains is prudent. Further consideration

must be given to the appropriate number of targets contained in a pan-family test to increase the likelihood that a novel pathogen is captured by an established assay, as well as the appropriate validation processes which should be undertaken following pathogen emergence before the approved use of a pan-family assay.

261

262 Our analysis has highlighted several limitations of reported pan-family tests resulting from an 263 over-optimization on observed sequence variation rather than pre-emptive variation predicted 264 from highly conserved protein motifs. Indeed, with the target regions applied by the MPC assay 265 all possible genomic combinations translating to observed protein motifs are observed in the relatively small panel of reference coronaviruses. Broadening of primer degeneracy with the 266 267 strategies described in this work, as well as routine comparison with novel animal viruses may 268 assist in ensuring ongoing effectiveness of pan-family assays. However, highly degenerate 269 primers, such as the modified primers described in this work, are likely to have reduced test 270 sensitivity to viral load. This may be partially counteracted through the use of universal base analogues such as inosine or 5-nitroindole³³ to reduced degeneracy or avoided through more 271 272 judicious targeting of alternative highly conserved genomic motifs⁹. An alternative strategy 273 may be the use of more relaxed reaction conditions to accommodate minor primer mismatches, 274 though this may further reduce assay specificity²⁹. These limitations must be appropriately 275 characterized as part of pan-family assay development if to be applied in a clinical context.

276

A panel of pan-family assays would be required to provide a more robust tool for combating novel pathogens, with priority given to viral families associated with previous epidemics. Panfamily assays have been described for multiple viral families associated with recent epidemics, including filoviruses (Ebola Virus)³⁴ and flaviviruses (Zika Virus, Dengue Virus, Yellow Fever Virus)³⁵, and a similar analysis to the one presented here should be performed to assess the

specificity and sensitivity of these assays for novel pathogens within the context of common viral species. Consistency in reaction conditions between pan-family assays or multiplexing of several assays into a single kit may further simplify the application of these tools during emerging pandemics.

286

287 A cost-effectiveness analysis of stockpiling pan-family assays is beyond the scope of this work 288 given the novelty of the proposed testing strategies, and the unpredictability of pandemic 289 emergence and characteristics. Most components required to run pan-family assays (nucleic 290 acid-extraction kits, enzymes and buffers) may already be already sufficiently stocked by 291 diagnostic laboratories or may be able to be repurposed for routine testing or research 292 applications towards the end of their shelf life. The only unique components required are the 293 specific test primers, which depending on oligonucleotide modifications, number of reactions 294 and production volume can be expected to cost below 0.5USD/test, with a shelf life of at least 295 2 years. However, to increase the simplicity and rapidity of testing it may be practical to 296 stockpile all reagents required to run a pan-family assay as part of a self-contained test-kit, 297 despite the additional cost.

298

299 Strategic stockpiling of pan-family viral assays is a proactive alternative to current viral disease 300 test strategies which may expedite testing during emerging pandemics. These assays have the 301 potential to greatly assist management of emerging public health emergencies through 302 prioritization of high-resolution testing or isolation measures, despite limitations in test 303 specificity due to cross-reactivity with common pathogens. Extensive further development, 304 validation and certification of pan-family assays is needed prior to application in broad clinical 305 contexts. With appropriate design these tools may allow informative and high-throughput 306 screening of millions of individuals within days of pathogen emergence.

307 Supplementary Table

308 Supplementary Table 1

- 309 60 Coronavirus-family reference sequences used in this study and the nucleic acid sequence
- 310 observed the MPC Primer Target Sites⁷. Genomic sequences which match the primer target
- 311 sequences are highlighted in green while those which contain a variant not matching the
- 312 primer target sequences are highlighted in orange. A consensus sequence for all observed
- 313 variation is shown at the bottom of the table.

Species	MPC Forward Target	MPC Reverse Target
MPC Primer Targets	ACWCARHTVAAYYTNAARTAYGC	TGGGAYTAYCCHAARTGYGA
Alphacoronavirus_1_ NC_002306	ACTCAAATGAATTTGAAATATGC	TGGGACTATCCTAAGTGTGA
Alphacoronavirus_1_ Sus_scrofa NC_028806	ACTCAACTGAATTTGAAATACGC	TGGGACTATCCTAAGTGTGA
Alphacoronavirus_1_ Sus_scrofa NC_038861	ACTCAAATGAATTTGAAATACGC	TGGGACTATCCTAAGTGTGA
Alphacoronavirus_Bat-CoV/P_kuhlii/Italy/3398- 19/2015_ Pipistrellus_kuhlii NC_046964	ACGCAACTCAATCTCAAGTATGC	TGGGATTACCCTAAGTGTGA
Avian_coronavirus_ NC_001451	ACTCAAATGAATTTAAAATATGC	TGGGATTATCCTAAGTGTGA
Avian_coronavirus_ Meleagris_gallopavo NC_010800	ACTCAAATGAATTTAAAATATGC	TGGGATTATCCAAAGTGTGA
Bat_coronavirus_ Pipistrellus NC_034440	ACTCAAATGAATTTAAAGTATGC	TGGGATTACCCTAAGTGTGA
Bat_coronavirus_1A_ NC_010437	ACACAACTTAATCTTAAGTATGC	TGGGACTATCCTAAATGTGA
Bat_coronavirus_BM48- _31/BGR/2008_ Rhinolophus_blasii NC_014470	ACTCAGATGAATCTTAAATATGC	TGGGATTACCCAAAATGTGA
Bat_coronavirus_CDPHE15_ Myotis_lucifugus NC_022103	ACTCAGCTCAACTTAAAGTACGC	TGGGACTATCCGAAGTGTGA
Bat_coronavirus_HKU10_ Chiroptera NC_018871	ACACAGCTCAACTTAAAGTATGC	TGGGACTACCCTAAGTGTGA
Bat_Hp- betacoronavirus_Zhejiang2013_ Hipposideros_pratti NC_02 5217	ACTCAAATGAATTTGAAATATGC	TGGGATTATCCTAAGTGTGA
Beluga_whale_coronavirus_SW1_ Delphinapterus_leucas NC_ 010646	ACCCAGATTAATATGAAGTATGC	TGGGACTATCCTAAGTGTGA
Betacoronavirus_1_ NC_003045	ACTCAAATGAATTTGAAATATGC	TGGGATTATCCTAAGTGTGA
Betacoronavirus_1_ NC_006213	ACTCAAATGAATTTGAAATATGC	TGGGATTATCCTAAGTGTGA
BtRf- AlphaCoV/YN2012_ Rhinolophus_ferrumequinum NC_028824	ACACAGCTTAATCTTAAGTATTC	TGGGATTATCCTAAATGTGA
Bulbul_coronavirus_HKU11_ Pycnonotus_jocosus NC_011547	ACGCAGATGAATCTTAAGTATGC	TGGGATTACCCCAAGTGTGA
Canada_goose_coronavirus_ Branta_canadensis NC_046965	ACTCAGATGAATTTGAAATATGC	TGGGACTATCCTAAATGTGA
China_Rattus_coronavirus_HKU24_ Rattus_norvegicus NC_02 6011	ACCCAAATGAATCTTAAATATGC	TGGGATTATCCTAAGTGCGA
Common_moorhen_coronavirus_HKU21_ Gallinula_chloropus N _C_016996	ACTCAAATGAACTTGAAATATGC	TGGGATTATCCTAAGTGTGA
Coronavirus_AcCoV-JC34_ Apodemus_chevrieri NC_034972	ACACAGCTTAATCTTAAGTATGC	TGGGATTATCCAAAATGTGA
Coronavirus_HKU15_ Sus_scrofa NC_039208	ACTCAGATGAACCTTAAGTATGC	TGGGATTACCCTAAGTGTGA
Ferret_coronavirus_ Mustela_putorius NC_030292	ACACAGATGAATCTTAAGTATGC	TGGGATTACCCCAAGTGTGA
Hedgehog_coronavirus_1_ Erinaceus_europaeus NC_039207	ACTCAAATGAATTTAAAGTATGC	TGGGATTACCCTAAGTGTGA
Human_coronavirus_229E_ NC_002645	ACTCAGTTAAATCTTAAATACGC	TGGGACTATCCTAAGTGTGA
Human_coronavirus_229E_ Camelus NC_028752	ACTCAGTTAAATCTCAAATACGC	TGGGACTATCCTAAGTGTGA

Human_coronavirus_HKU1_ Homo_sapiens NC_006577	ACTCAAATGAATTTAAAATATGC	TGGGATTATCCTAAATGTGA
Human_coronavirus_NL63_ NC_005831	ACACAGCTGAATCTTAAGTATGC	TGGGATTATCCCAAATGTGA
Lucheng_Rn_rat_coronavirus_ Rattus_norvegicus NC_032730	ACGCAGCTTAATCTTAAGTATGC	TGGGACTATCCCAAGTGTGA
Magpie-robin_coronavirus_HKU18_ Muscicapidae NC_016993	ACTCAGATGAACCTCAAATATGC	TGGGATTACCCTAAGTGTGA
Middle_East_respiratory_syndrome-	ΑCTCAAATGAATCTAAAATATGC	TGGGATTACCCTAAGTGTGA
Middle_East_respiratory_syndrome-		TOCONTRACTOR
related_coronavirus_[Homo_sapiens]NC_038294		
Miniopterus_bat_coronavirus_HKU8_ NC_010438	ACACAGETTAACETTAAGTATGE	
Mink_coronavirus_1_Neovison_visonNC_023760		
Munia_coronavirus_HKU13_ Lonchura_striata NC_011550		
_Murine_coronavirus_ AC_000192	ACICAAAIGAAICIIAAAIAIGC	
_Murine_coronavirus_ NC_001846	ACTCAAATGAATCTTAAATATGC	TGGGACTATCCTAAATGTGA
Murine_coronavirus_RattusNC_012936	ACTCAAATGAATCTTAAATATGC	TGGGACTATCCTAAGTGTGA
2011_ Myotis_ricketti NC_028811	ACACAGCTTAATCTTAAGTATGC	TGGGACTATCCTAAGTGTGA
Night_heron_coronavirus_HKU19_ Ardeidae NC_016994	ACGCAAATGAATCTCAAATATGC	TGGGATTACCCTAAGTGTGA
NL63-related_bat_coronavirus_strain_BtKYNL63- 9b_ Triaenops_afer NC_032107	ACTCAATTGAATCTTAAGTATGC	TGGGACTATCCAAAATGTGA
Nyctalus_velutinus_alphacoronavirus_SC- 2013 Nyctalus velutinus NC 028833	ACGCAGCTTAATCTCAAGTATGC	TGGGACTACCCTAAGTGTGA
Pipistrellus_bat_coronavirus_HKU5_ Chiroptera NC_009020	ACGCAGATGAATTTGAAATATGC	TGGGATTACCCCAAGTGTGA
Porcine_epidemic_diarrhea_virus_ NC_003436	ACACAGCTCAACCTTAAATACGC	TGGGATTACCCAAAGTGCGA
Rabbit_coronavirus_HKU14_ Oryctolagus_cuniculus NC_0170 83	ACACAAATGAACCTTAAGTATGC	TGGGATTATCCAAAATGTGA
Rhinolophus_bat_coronavirus_HKU2_ NC_009988	ACACAGCTTAATCTCAAGTATTC	TGGGATTATCCTAAATGTGA
Rhinolophus_ferrumequinum_alphacoronavirus_HuB- 2013 Rhinolophus_ferrumequinum NC_028814	ACACAGCTTAATCTTAAATATGC	TGGGACTACCCGAAGTGTGA
Rodent coronavirus Myodes rufocanus NC 046954	ACACAGATGAATCTTAAGTATGC	TGGGATTATCCTAAATGTGA
Rousettus_bat_coronavirus_GCCDC1_ Rousettus_leschenault	Αςτελελτελλτττελλετλτες	Тесситтоссталетесса
_ Rousettus_bat_coronavirus_HKU9_ Chiroptera NC_009021	ACTCAGATGAATTTGAAGTATGC	
Scotophilus_bat_coronavirus_512_ NC_009657	ACCCAGCITAATTIGAAGTATGC	IGGGATIAICCIAAGIGIGA
related_coronavirus_ NC_004718	ACTCAAATGAATCTTAAGTATGC	TGGGATTATCCAAAATGTGA
Severe_acute_respiratory_syndrome- related_coronavirus_ Homo_sapiens NC_045512	ACTCAAATGAATCTTAAGTATGC	TGGGATTATCCTAAATGTGA
Shrew_coronavirus_ Sorex_araneus NC_046955	ACGCAAGTTAATTTAAAATATGC	TGGGATTACCCTAAATGTGA
Sparrow_coronavirus_HKU17_ Passeridae NC_016992	ACTCAGATGAACCTTAAGTATGC	TGGGATTACCCCAAGTGTGA
Thrush_coronavirus_HKU12_ Turdus_hortulorum NC_011549	ACTCAAATGAATCTTAAATATGC	TGGGATTACCCTAAGTGTGA
Tylonycteris_bat_coronavirus_HKU4_ Chiroptera NC_009019	ACTCAAATGAATTTGAAGTATGC	TGGGATTACCCTAAGTGTGA
Wencheng_Sm_shrew_coronavirus_ Suncus_murinus NC_035191	ACGCAAATGAATCTTAAGTATGC	TGGGATTATCCCAAATGTGA
White-eye_coronavirus_HKU16_ Zosteropidae NC_016991	ACTCAGATGAATCTTAAGTATGC	TGGGATTACCCTAAGTGTGA
Wigeon_coronavirus_HKU20_ Mareca NC_016995	ACACAGATGAATCTAAAGTATGC	TGGGATTATCCTAAATGTGA
Consensus DNA	ACNCARNTNAAYHTNAARTAYKC	TGGGAYTAYCCNAARTGYGA

315 Supplementary Table 2

- 316 20 Coronavirus species with novel variation in the MPC Target sites and the effect of this variation on the protein motif encoded by this site.
- 317 Silent mutations are highlighted in blue while missense mutations are highlighted in orange.

Species	MPC Forward Target	Mutation Type	MPC Reverse Target	Mutation Type
MPC Primer Targets	ACWCARHTVAAYYTNAARTAYGC		<u>TGGGAYTAYCCHAARTGYGA</u>	
Alphacoronavirus_Bat-CoV/P_kuhlii/Italy/3398-19/2015_ Pipistrellus_kuhlii NC_046964	ACGCAACTCAATCTCAAGTATGC	Silent		
Bat_coronavirus_1A_ NC_010437	ACACAACTTAATCTTAAGTATGC	Silent		
Bat_coronavirus_CDPHE15_ Myotis_lucifugus NC_022103	ACTCAGCTCAACTTAAAGTACGC	Silent	TGGGACTATCCGAAGTGTGA	Silent
Beluga whale coronavirus SW1 Delphinapterus leucas NC 010646	ACCCAGATTAATATGAAGTATGC	Missense		
BtRf-AlphaCoV/YN2012 Rhinolophus ferrumequinum NC 028824	ACACAGCTTAATCTTAAGTATTC	Missense		
Bulbul coronavirus HKU11 Pycnonotus jocosus NC 011547	ACGCAGATGAATCTTAAGTATGC	Silent		
China Rattus coronavirus HKU24 Rattus norvegicus NC 026011	ACCCAAATGAATCTTAAATATGC	Silent		
Coronavirus AcCoV-JC34 Apodemus chevrieri NC 034972	ACACAGCTTAATCTTAAGTATGC	Silent		
Lucheng Rn rat coronavirus Rattus norvegicus NC 032730	ΑΓΩΓΑΩ	Silent		
Minionterus hat coronavirus HKU8 NC 010438		Silent		
Mink coronavirus 1 Neovison vison NC 023760	ACACAGETTAACCTTAAGTATGC	Silenc		Silent
Myotis rickatti alnhacoronavirus Sav-2011 Myotis rickatti NC 028811	ΔΟΛΟΛΟΟΤΙΑΛΙΟΤΙΑΛΟΤΑΙΟΟ	Silent	TOGORTIAI COMMITTION	Silenc
Night heron coronavirus HKI19 Ardeidae NC 016994		Silent		
Nuctolus volutinus alphasenenenvinus 50 2012 Nuctolus volutinus NC 020022		Silent		
		Silent		
		Missen		
KNINOIOPNUS_BAT_COPONAVIPUS_HKU2_ NC_009988	ACACAGCITAATCTCAAGTATTC	Missense		
Rhinolophus_ferrumequinum_alphacoronavirus_HuB-2013_ Rhinolophus_ferrumequinum NC_028814	ACACAGCTTAATCTTAAATATGC	Silent	TGGGACTACCCGAAGTGTGA	Silent
Scotophilus_bat_coronavirus_512_ NC_009657	ACCCAGCTTAATTTGAAGTATGC	Silent		
Shrew_coronavirus_ Sorex_araneus NC_046955	ACGCAAGTTAATTTAAAATATGC	Missense		
Wencheng_Sm_shrew_coronavirus_ Suncus_murinus NC_035191	ACGCAAATGAATCTTAAGTATGC	Silent		

319 Supplementary Table 3

- 320 60 Coronavirus-family reference sequences used in this study and the protein sequence
- 321 encoded by the MPC Assay Primer Target Sites⁷. A protein and nucleic acid consensus
- 322 sequence for all observed variation is shown at the bottom of the table.

Species	MPC Forward Target	MPC Reverse Target
Alphacoronavirus_1_ NC_002306	TQMNLKYA	WDYPKCD
Alphacoronavirus_1_ Sus_scrofa NC_028806	TQLNLKYA	WDYPKCD
Alphacoronavirus_1_ Sus_scrofa NC_038861	TQMNLKYA	WDYPKCD
Alphacoronavirus_Bat-CoV/P_kuhlii/Italy/3398- 19/2015_ Pipistrellus_kuhlii NC_046964	TQLNLKYA	WDYPKCD
Avian_coronavirus_ NC_001451	TQMNLKYA	WDYPKCD
Avian_coronavirus_ Meleagris_gallopavo NC_010800	TQMNLKYA	WDYPKCD
Bat_coronavirus_ Pipistrellus NC_034440	TQMNLKYA	WDYPKCD
Bat_coronavirus_1A_ NC_010437	TQMNLKYA	WDYPKCD
Bat_coronavirus_BM48- 31/BGR/2008_ Rhinolophus_blasii NC_014470	TQLNLKYA	WDYPKCD
Bat_coronavirus_CDPHE15_ Myotis_lucifugus NC_0221 03	TQMNLKYA	WDYPKCD
Bat_coronavirus_HKU10_ Chiroptera NC_018871	TQLNLKYA	WDYPKCD
Bat_Hp- betacoronavirus_Zhejiang2013_ Hipposideros_pratti NC_025217	TQLNLKYA	WDYPKCD
Beluga_whale_coronavirus_SW1_ Delphinapterus_leuc as NC_010646	TQINMKYA	WDYPKCD
Betacoronavirus_1_ NC_003045	TQMNLKYA	WDYPKCD
Betacoronavirus_1_ NC_006213	TQMNLKYA	WDYPKCD
BtRf- AlphaCoV/YN2012_ Rhinolophus_ferrumequinum NC_028 824	TQLNLKYS	WDYPKCD
Bulbul_coronavirus_HKU11_ Pycnonotus_jocosus NC_0 11547	TQMNLKYA	WDYPKCD
Canada_goose_coronavirus_ Branta_canadensis NC_04 6965	TQMNLKYA	WDYPKCD
China_Rattus_coronavirus_HKU24_ Rattus_norvegicus NC_026011	TQMNLKYA	WDYPKCD
Common_moorhen_coronavirus_HKU21_ Gallinula_chlor opus NC_016996	TQMNLKYA	WDYPKCD
Coronavirus_AcCoV- JC34_ Apodemus_chevrieri NC_034972	TQLNLKYA	WDYPKCD
Coronavirus_HKU15_ Sus_scrofa NC_039208	TQMNLKYA	WDYPKCD
Ferret_coronavirus_ Mustela_putorius NC_030292	TQMNLKYA	WDYPKCD
Hedgehog_coronavirus_1_ Erinaceus_europaeus NC_03 9207	TQMNLKYA	WDYPKCD
Human_coronavirus_229E_ NC_002645	TQLNLKYA	WDYPKCD
Human_coronavirus_229E_ Camelus NC_028752	TQLNLKYA	WDYPKCD
Human_coronavirus_HKU1_ Homo_sapiens NC_006577	TQMNLKYA	WDYPKCD
Human_coronavirus_NL63_ NC_005831	TQLNLKYA	WDYPKCD
Lucheng_Rn_rat_coronavirus_ Rattus_norvegicus NC_ 032730	TQLNLKYA	WDYPKCD
Magpie- robin_coronavirus_HKU18_ Muscicapidae NC 016993	TQMNLKYA	WDYPKCD

Middle_East_respiratory_syndrome- related coronavirus Homo sapiens NC 019843G	TOMNLKYA	WDYPKCD
Middle_East_respiratory_syndrome- related coronavirus Homo sapiens NC 038294	TOMNLKYA	WDYPKCD
Miniopterus bat coronavirus HKU8 NC 010438	TOLNLKYA	WDYPKCD
Mink coronavirus 1 Neovison vison NC 023760	TQMNLKYA	WDYPKCD
Munia_coronavirus_HKU13_ Lonchura_striata NC_0115 50	TQMNLKYA	WDYPKCD
Murine_coronavirus_ AC_000192	TQMNLKYA	WDYPKCD
Murine_coronavirus_ NC_001846	TQMNLKYA	WDYPKCD
Murine coronavirus Rattus NC 012936	TQMNLKYA	WDYPKCD
Myotis_ricketti_alphacoronavirus_Sax- 2011_ Myotis_ricketti NC_028811	TQLNLKYA	WDYPKCD
Night_heron_coronavirus_HKU19_ Ardeidae NC_016994	TQLNLKYA	WDYPKCD
NL63-related_bat_coronavirus_strain_BtKYNL63- 9b_ Triaenops_afer NC_032107	TQMNLKYA	WDYPKCD
Nyctalus_velutinus_alphacoronavirus_SC- 2013_Nyctalus_velutinusNC_028833	TQLNLKYA	WDYPKCD
Pipistrellus_bat_coronavirus_HKU5_ Chiroptera NC_ 009020	TQMNLKYA	WDYPKCD
Porcine_epidemic_diarrhea_virus_ NC_003436	TQLNLKYA	WDYPKCD
Rabbit_coronavirus_HKU14_ Oryctolagus_cuniculus N _C_017083	TQMNLKYA	WDYPKCD
Rhinolophus_bat_coronavirus_HKU2_ NC_009988	TQLNLKYS	WDYPKCD
Rhinolophus_ferrumequinum_alphacoronavirus_HuB- 2013_ Rhinolophus_ferrumequinum NC_028814	TQLNLKYA	WDYPKCD
Rodent_coronavirus_ Myodes_rufocanus NC_046954	TQMNLKYA	WDYPKCD
<pre>Rousettus_bat_coronavirus_GCCDC1_ Rousettus_lesch enaultii NC_030886</pre>	TQMNLKYA	WDYPKCD
Rousettus_bat_coronavirus_HKU9_ Chiroptera NC_009 021	TQMNLKYA	WDYPKCD
Scotophilus_bat_coronavirus_512_ NC_009657	TQLNLKYA	WDYPKCD
<pre>Severe_acute_respiratory_syndrome- related_coronavirus_ NC_004718</pre>	TQMNLKYA	WDYPKCD
Severe_acute_respiratory_syndrome- related_coronavirus_ Homo_sapiens NC_045512	TQMNLKYA	WDYPKCD
Shrew_coronavirus_ Sorex_araneus NC_046955	TQVNLKYA	WDYPKCD
Sparrow_coronavirus_HKU17_ Passeridae NC_016992	TQMNLKYA	WDYPKCD
Thrush_coronavirus_HKU12_ Turdus_hortulorum NC_01 1549	TQMNLKYA	WDYPKCD
Tylonycteris_bat_coronavirus_HKU4_ Chiroptera NC_ 009019	TQMNLKYA	WDYPKCD
Wencheng_Sm_shrew_coronavirus_ Suncus_murinus NC_ 035191	TQMNLKYA	WDYPKCD
White- eye_coronavirus_HKU16_ Zosteropidae NC_016991	TQMNLKYA	WDYPKCD
Wigeon_coronavirus_HKU20_ Mareca NC_016995	TQMNLKYA	WDYPKCD
Consensus Protein	TQ(I/M/L/V)N(L/M)KY(A/S)	WDYPKCD
Consensus Reverse Translation	ACNCARNTNAAYHTNAARTAYKC	TGGGAYTAYCCNAARTGYGA
Consensus DNA	ACNCARNTNAAYHTNAARTAYKC	TGGGAYTAYCCNAARTGYGA

325 Supplementary Table 4: Revised Pan-Coronavirus primers accommodating observed

326 nucleic acid and protein sequences. Modified Targets (Observed Variation) describe the 327 degenerate primer sequences required to accommodate all observed genomic variation 328 (supplementary table 1). Modified Targets (Reverse Translated) describe a degenerate primer 329 target sequence designed using the reverse translation of the observed protein sequences 330 encoding the primer target sites (supplementary table 3).

331

	Forward Primer	Reverse Primer
MPC Primer Targets	ACWCARHTVAAYYTNAARTAYGC	TGGGAYTAYCCHAARTGYGA
Modified Targets (Observed Variation)	AC <u>N</u> CAR <u>N</u> T <u>N</u> AAY <u>H</u> TNAARTAY <u>K</u> C	TGGGAYTAYCC <u>N</u> AARTGYGA
Modified Targets (Reverse Translated)	AC <u>N</u> CAR <u>N</u> T <u>N</u> AAY <u>H</u> TNAARTAY <u>K</u> C	TGGGAYTAYCC <u>N</u> AARTGYGA

332

334 References

225	1	
335	1	Zou, L. <i>et al.</i> SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.
336	•	New England Journal of Medicine 382 , 1177-1179, doi:10.1056/NEJMc2001737 (2020).
337	2	Hadaya, J., Schumm, M. & Livingston, E. H. Testing Individuals for Coronavirus Disease
338		2019 (COVID-19). <i>JAMA</i> , doi:10.1001/jama.2020.5388 (2020).
339	3	Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A.
340		Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England
341		<i>Journal of Medicine</i> 367 , 1814-1820 (2012).
342	4	Cabeça, T. K., Passos, A. M., Granato, C. & Bellei, N. Human coronavirus ocurrence in
343		different populations of Sao Paulo: a comprehensive nine-year study using a pancoronavirus
344		RT-PCR assay. Brazilian Journal of Microbiology 44, 335-339 (2013).
345	5	Hatcher, E. L. et al. Virus Variation Resource - improved response to emergent viral
346		outbreaks. Nucleic Acids Res 45, D482-D490, doi:10.1093/nar/gkw1065 (2017).
347	6	Stephensen, C. B., Casebolt, D. B. & Gangopadhyay, N. N. Phylogenetic analysis of a highly
348		conserved region of the polymerase gene from 11 coronaviruses and development of a
349		consensus polymerase chain reaction assay. Virus Res 60, 181-189, doi:10.1016/s0168-
350		1702(99)00017-9 (1999)
351	7	Vijgen I. Moës E. Keyaerts E. Li S. & Van Ranst M in SARS-and Other Coronaviruses
352	/	3-12 (Springer 2008)
353	8	de Souza Luna L K <i>et al</i> Generic Detection of Coronaviruses and Differentiation at the
354	0	Prototype Strain Level by Reverse Transcription-PCR and Nonfluorescent Low-Density
355		Microarray I Clin Microbiol 45, 1049-1052, doi:10.1128/icm.02426-06 (2007)
356	0	Hu H Jung K Wang O Saif I I & Vlasova A N Development of a one step BT PCP
357	2	A assay for detection of pancoronaviruses (α , β , γ , and δ coronaviruses) using newly designed
358		degenerate primers for parcorola and avianfecol somples. <i>Journal of vivological methods</i> 256
250		116 122 (2018)
260	10	110-122 (2010). Madaira E at al The EMDI EDI acorah and acqueres analysis tools ADIs in 2010 Nucleis
361	10	Acide Res A7 W626 W641 doi:10.1002/nor/gkz268 (2010)
362	11	Files S. & Puelcland Morrett G. Data disease and diplomacy: CISAID's innovative
262	11	contribution to global health Clabal Challenges 1, 22, 46, doi:10.1002/gab2.1018 (2017)
264	10	Contribution to global health. Global Challenges 1, 55-40, doi:10.1002/gch2.1018 (2017).
265	12	historical strings. B nachano useriar 2 (2017)
266	10	biological strings. <i>R package version 2</i> (2017).
300	13	Kissier, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the
30/	14	transmission dynamics of SARS-Cov-2 through the postpandemic period. Science (2020).
368	14	Zhou, W., Wang, W., Wang, H., Lu, R. & Tan, W. First infection by all four non-severe acute
309		respiratory syndrome human coronaviruses takes place during childhood. BMC Infectious
370		Diseases 13, 433, doi:10.1186/14/1-2334-13-433 (2013).
371	15	Gorse, G. J., Donovan, M. M. & Patel, G. B. Antibodies to coronaviruses are higher in older
372		compared with younger adults and binding antibodies are more sensitive than neutralizing
373		antibodies in identifying coronavirus-associated illnesses. Journal of Medical Virology.
374	16	Aldridge, R. <i>et al.</i> Seasonality and immunity to laboratory-confirmed seasonal coronaviruses
375		(HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
376		[version 1; peer review: awaiting peer review]. Wellcome Open Research 5,
377		doi:10.12688/wellcomeopenres.15812.1 (2020).
378	17	van der Zalm, M. M. et al. Respiratory pathogens in children with and without respiratory
379		symptoms. J Pediatr 154, 396-400.e391, doi:10.1016/j.jpeds.2008.08.036 (2009).
380	18	Gaunt, E. R., Hardie, A., Claas, E. C. J., Simmonds, P. & Templeton, K. E. Epidemiology and
381		clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43
382		detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48,
383		2940-2947, doi:10.1128/JCM.00636-10 (2010).

384	19	Prill, M. M. et al. Human coronavirus in young children hospitalized for acute respiratory
385		illness and asymptomatic controls. Pediatr Infect Dis J 31, 235-240,
386		doi:10.1097/INF.0b013e31823e07fe (2012).
387	20	Cabeça, T. K., Granato, C. & Bellei, N. Epidemiological and clinical features of human
388		coronavirus infections among different subsets of patients. Influenza Other Respir Viruses 7,
389		1040-1047, doi:10.1111/irv.12101 (2013).
390	21	Lepiller, Q. et al. High incidence but low burden of coronaviruses and preferential
391		associations between respiratory viruses. J Clin Microbiol 51, 3039-3046.
392		doi:10.1128/JCM.01078-13 (2013).
393	22	Matoba, Y. et al. Detection of the Human Coronavirus 229E, HKU1, NL63, and OC43
394		between 2010 and 2013 in Yamagata, Japan, Japanese Journal of Infectious Diseases 68.
395		138-141. doi:10.7883/voken.JJID.2014.266 (2015).
396	23	Zhang, Y. <i>et al.</i> Burden of respiratory syncytial virus infections in China: Systematic review
397		and meta-analysis J Glob Health 5, 020417-020417, doi:10.7189/jogh.05.020417 (2015)
398	24	Yin C. C. <i>et al.</i> A six-year descriptive epidemiological study of human coronavirus infections
399	21	in hospitalized nations in Hong Kong Virologica Sinica 31 41-48 (2016)
400	25	Liu P <i>et al</i> Prevalence and genetic diversity analysis of human coronaviruses among cross-
401	20	border children <i>Viral I</i> 14 230-230 doi:10.1186/s12985-017-0896-0 (2017)
402	26	Zeng Z -O <i>et al.</i> Enidemiology and clinical characteristics of human coronaviruses OC43
403	20	229E, NI 63, and HKU1: a study of hospitalized children with acute respiratory tract infection
404		in Guangzhou China European Journal of Clinical Microbiology & Infectious Diseases 37
405		363-369 doi:10.1007/s10096-017-3144-7 (2018)
406	27	Killerby M F <i>et al</i> Human coronavirus circulation in the United States 2014–2017 <i>Journal</i>
407	27	of Clinical Virology 101 52-56 doi:https://doi.org/10.1016/j.jcy.2018.01.019 (2018)
408	28	Heimdal L et al. Human Coronavirus in Hospitalized Children With Respiratory Tract
409	20	Infections: A 9-Year Population-Based Study From Norway <i>J Infect Dis</i> 219 1198-1206
410		doi:10.1093/infdis/iiv646 (2019)
411	29	Stadhouders R <i>et al.</i> The effect of primer-template mismatches on the detection and
412	2)	quantification of nucleic acids using the 5' nuclease assay. The Journal of Molecular
413		Diagnostics 12, 109-117 (2010)
414	30	Wan Z et al. A Melting Curve-Based Multiplex RT-aPCR Assay for Simultaneous Detection
415	50	of Four Human Coronaviruses International journal of molecular sciences 17 1880
416		doi:10.3390/jims17111880 (2016)
417	31	Maxmen A Thousands of coronavirus tests are going unused in US labs <i>Nature</i> (2020)
-17 /18	32	Lippi G. Simundic, A. M. & Plebani, M. Potential preanalytical and analytical
-10 /10	52	yulnerabilities in the laboratory diagnosis of coronavirus disease 2010 (COVID 10) <i>Clinical</i>
420		Chemistry and Laboratory Medicine (CCLM) 1 (2020)
420 421	22	Lookes D & Brown D M 5 Nitroindole as an universal base analogue. Nucleic acids
$\frac{1}{121}$	33	Loakes, D. & Diowii, D. Wi. 5-Nitroindole as an universal base analogue. Nucleic uclus research 22 A030 A043 doi:10.1003/nor/22.20.4030 (1004)
422	21	Vern K et al Dan filoximus one sten reverse transcription nolymerose chain reaction
423	54	screening assay hie Prin 570458 doi:10.1101/570458 (2010)
-⊤∠- 1 ∕/25	35	Vina Rodriguez A at al A Novel Pan Flavivirus Detection and Identification Assay Decad
425 426	55	on RT-aPCR and Microarray Riomod Res Int 2017 A248756 A248756
420 427		doi:10.1155/2017/ $A248756$ (2017)
-T <i>L</i> /		401.10.1133/2017/7470730(2017).
400		